A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

September 12, 2023

Study Completion Date

October 13, 2023

Conditions
CirrhosisAscitesHepatorenal SyndromeAcute Kidney Injury
Interventions
DRUG

OCE-205

The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.

DRUG

Placebo

Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.

Trial Locations (23)

10065

New York-Presbyterian Hospital, New York

20007

MedStar Georgetown University Hospital, Washington D.C.

21201

University of Maryland Medical Center, Baltimore

23249

McGuire VA Medical Center, Richmond

23298

Virginia Commonwealth University Health System, Richmond

29425

Medical University of South Carolina, Charleston

30309

Piedmont Atlanta Hospital, Atlanta

33606

Tampa General Medical Group, Tampa

45219

University of Cincinnati Medical Center, Cincinnati

46202

Indiana University Hospital, Indianapolis

55455

M Health Fairview University of Minnesota Medical Center, Minneapolis

55905

Mayo Clinic, Rochester

60611

Northwestern Medicine, Chicago

65212

University of Missouri, Columbia

75246

Baylor University, Dallas

77030

CHI St Luke's Health Baylor College of Medicine Medical Center, Houston

85054

Mayo Clinic - Phoenix, Phoenix

90033

Keck Medical Center of USC, Los Angeles

94143

University of California, San Francisco Liver Clinic, San Francisco

94305

Stanford Hospital, Stanford

02144

Massachusetts General Hospital, Boston

07103

Rutgers New Jersey Medical School, Newark

M5G 2C4

Toronto General Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ocelot Bio, Inc

INDUSTRY